Infliximab does not suppress the tuberculin skin test (purified protein derivative)

Hatemi G., Melikoglu M., Fresko I., Masatlioglu S., Tascilar K., Yazici H.

JOURNAL OF RHEUMATOLOGY, vol.34, no.3, pp.474-480, 2007 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 34 Issue: 3
  • Publication Date: 2007
  • Journal Name: JOURNAL OF RHEUMATOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.474-480
  • Istanbul University Affiliated: Yes

Abstract

Objective. Tuberculin skin testing with purified protein derivative (PPD) is part of tuberculosis (TB) screening in patients receiving infliximab. We assessed whether infliximab, a strong inhibitor of inflammation, suppressed dermal induration, the outcome of this test. We also reassessed the booster phenomenon and the interobserver variability in tuberculin testing.